About: enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.58 (-3.07%)
ENGN NASDAQ enGene Holdings Inc. Common Stock
enGene Holdings Inc. Common Stock share price
Atividade de preço de ENGN
Último preço
$ 1,580
Variação (24h)
-0,05 USD (3,07%)
Volume
554.58K
Volume (média 4 sem.)
-
Abertura
$ 1,62
Variação do dia
$ 1,57 - $ 1,65
Fechamento anterior
$ 1,63
Último negócio
22 Oct, 8:00 pm GMT+0
Atrasado
22 Oct, 8:00 pm GMT+0
ENGN price performance
Atrasado
22 Oct, 8:00 pm GMT+0
quote.marketSignals